Cancer diagnosis, AI and regulatory issues
We are delighted to share with you the intervention of Juliette Renauld, founder and CEO of Genexpath, in the first episode of the podcast MED.Innov’created by Marianne Lahanahealth law attorney at Phusis Avocats.
In this fascinating exchange, Juliette Renauld looks back on the progress of Genexpath in the field of cancer diagnosis and on the regulatory and ethical challenges linked to health innovations.
On the program for this episode:
✅L’innovation au service du diagnostic
Genexpath développe des tests de diagnostic de nouvelle génération. Ces solutions améliorent la caractérisation des lymphomes non hodgkiniens et des sarcomes. Elles allient biologie moléculaire, séquençage de nouvelle génération (NGS) et intelligence artificielle.
✅ The challenges of CE marking
CE marking is essential for marketing a medical device in Europe. Juliette Renauld shares her experience and the key steps in this regulatory process.
✅ AI in health: opportunities and limits
Artificial intelligence is transforming medical diagnosis. However, its use raises ethical and regulatory questions. Protecting patient data remains a priority.
✅ Reimbursement of innovative medical devices
After CE marking, access to reimbursement is another challenge. Marianne Lahana explains the steps to follow and the impact of the Reference Framework for Non-Nomenclature Investigations (RIHN).
Thanks to Marianne Lahana for this enriching exchange and Hub FranceIA for this partnership which highlights technological advances in the service of health.
To know more about Genexpath and our innovations in oncological diagnosis, visit 🌐 www.genexpath.com.